Tryptamine, 5-methoxy-α,N-dimethyl · Indole, 5-methoxy-3-[2-(methylamino)propyl] · 5-Methoxy-α,N-dimethyltryptamine · 5-Methoxy-3-[2-(methylamino)propyl]indole · α,N,O-Trimethylserotonin · Serotonin, α,N,O-trimethyl
SYNTHESIS: To a solution of 1.21 g 5-methoxyindole-3-carboxaldehyde in 15 mL nitroethane there was added 0.3 g anhydrous ammonium acetate, and the mixture was held at steam-bath temperature. Periodic assay by TLC showed the reaction to be complete in 1.5 h. The volatiles were removed under vacuum, and the residue (1.58 g of rusty red crystals) was recrystallized from 15 mL boiling isopropanol IPA. After filtration and air-drying, there was obtained 1.24 g (82%) of 5-methoxy-3-(2-nitropropenyl)indole as dull gold crystals with a melting point of 178–179 °C. The literature value is 182–184 °C.
A suspension of 1.7 g electrolytic iron dust in 10 mL of 80% aqueous acetic acid was heated on the steam bath until there were clear signs of hydrogen evolution. To this stirred suspension there was added 0.50 g 5-methoxy-3-(2-nitropropenyl)indole a bit at a time, over the course of 2 min. The heating and stirring was continued for 30 min by which time TLC analysis (CH2Cl2/hexane, silica) showed the starting material to be gone, and there were two new spots, one slower moving and one at the origin. The reaction mixture was poured into 100 mL of a H2O/CH2Cl2 mixture, and filtered through paper. The two phases were separated, and the aqueous phases extracted with an additional 2×50 mL CH2Cl2. The pooled organic extracts were washed once with saturated aqueous K2CO3, and the solvent removed under vacuum. The resulting residue was distilled at 0.08 mm/Hg to give 5-methoxyindol-3-yl acetone as a colorless oil which came over at 215–230 °C. The product weighed 0.24 g, had a carbonyl absorption at 1710 cm-1, and had an acceptable fragmentation pattern by GCMS.
To 20 mL methanol, there was added 1.17 g of 5-methoxyindol-3-yl acetone, 4.3 g CH3NH2 hydrochloride, 0.5 g NaCNBH3 and sufficient concentrated HCl/MeOH to bring the pH down to a yellow color on damped, broad range pH paper. The reaction was stirred at room temperature, with periodic addition of more acid as needed, over the course of several days. The reaction mixture was poured into dilute sulfuric acid, washed twice with CH2Cl2, made basic with dilute NaOH, and extracted with 3×50 mL CH2Cl2. After the removal of the solvent under vacuum, the residue (0.76 g) was distilled at 180–190 °C at 0.05 mm/Hg to give 0.65 g α,N,O-trimethylserotonin (α,N,O-TMS) as a colorless oil. It did not crystallize, nor were any solid salts of it obtained. MS (in m/z): C3H8N+ 58 (100%); methoxyindolemethylene+ 161/160 (19, 7%); parent ion 218 (<1%).
DOSAGE: 10–20 mg, orally
DURATION: 6–8 hrs h
QUALITATIVE COMMENTS: (with 16 mg, orally) “It was maybe a plus two, but there wasn’t really much of anything. My body felt safe, was safe. The only strong negative, negative only to me, was the nature of my dreaming that night; shallow, a faint metallic flavor, a distinct lack of depth or dimension. A waste of good dreaming time.”
(with 16 mg, orally) “I got as far as this would go, at about an hour and a quarter. There was nothing in the visual field, but I was unquestionably somewhere. I was quite horny, and the erotic was both excellent and satisfying. Tried writing, and it seemed easy. There was no fantasy, no color enhancement, and not much in the way of eye-dilation or appetite loss. Nothing much anywhere at all. As with Oakland, no there, there. And by the seventh hour, there was baseline, with a residual feeling of having been cleansed.”
(with 20 mg, orally) “I was in quite a depressed state, but I don’t think it was the α,N,O α,N,O-TMS But it certainly didn’t lift the depression. Everything I saw confirmed my growing despair about the human race and I concluded, after a few hours, that we have doomed ourselves. I am tired at being angry at it all. Enough already.”
EXTENSIONS AND COMMENTARY: There is a sadness felt with most of the published efforts to form sweeping correlations between the structure of a molecule and its biological activity. This relationship is called a SAR, or a Structure Activity Relationship, and there are journals that are dedicated to just this form of analysis.
One needs a large collection of compounds of known structure, and all of them must be of known pharmacological activity. And one needs a computer of some sort. One considers all aspects of the structure such as bond energies, electronic charge densities, molecular lengths, widths and thicknesses, degrees of freedom or of constraint, anything that can be calculated or measured. Then one assigns an independent variable coefficient to everything, constructs some additive equation where these coefficients equal something else, and then compares that something else to the biological activity. Push the “go” button on the computer, and let everything be varied clear across the map, until the calculated solution of the equation makes the best match with the value of pharmacological activity. Then one has a SAR with a statistical measure of goodness of fit, and it then can be used to predict the activity of new structures, which are yet untried, pharmacologically.
And there is the essence of why this entire process is ineffective. Prediction is the heart of this procedure, and prediction is never brought to bear. Let us take a new structure that is not in the original collection of structures, and let us make a prediction as to its, let us say, psychedelic potency. But no one ever tries it out for any of a number of reasons. Maybe the new compound is never synthesized. Or maybe it is synthesized, but never evaluated pharmacologically. The synthesist does not care, or is uninterested, or is restrained by the legal complications that might ensue. Or he does explore it, but chooses not to publish. Almost never is a prediction tested. What is more likely to happen, is that a new input of biological activity and structure variation is uncovered (for which there is no published prediction) and this data is tossed into the mill, and a new set of “more valid” coefficients is calculated, and the SAR becomes touted as a more accurate predictor. But, always remember, that without prediction and challenge, there is no inventive value from the SAR game. It simply organizes what is known, but creates nothing new.
This is a role that I would have loved to see α,N,O-TMS play. At the time of its first synthesis its biological activity was, by definition, completely unknown. Let’s cast its shadow up against the structures that were known, and with known activity. What would you predict? The most logical archetype to use as a starting point is the primary amine homologue,
To base structures that are stimulants (
With this, now, as a challenge, predict for me the potency of
20 June 2018 · · Isomer Design
About TiHKAL · info
This version of Book II of TiHKAL is based on the Erowid online version created by Bo Lawler with the help of Erowid, from content generously provided in electronic format by the Authors.
The Erowid online version does not always align precisely with the printed version. Text appears to have been inserted, deleted, or changed at various points. Where the two are seen to diverge both the Erowid and print versions are given. Sharp-eyed readers are encouraged to report novel discrepancies.
As with PiHKAL, I’ve again attempted to reproduce the typographic style of the printed edition. I’ve again made minor changes to some chemical names in line with current nomenclature practice. Typically the change is little more than expanding a prefix or setting it in italics. The history page has further details.
“At the present time, restrictive laws are in force in the United States and it is very difficult for researchers to abide by the regulations which govern efforts to obtain legal approval to do work with these compounds in human beings.“No one who is lacking legal authorization should attempt the synthesis of any of the compounds described in these files, with the intent to give them to man. To do so is to risk legal action which might lead to the tragic ruination of a life. It should also be noted that any person anywhere who experiments on himself, or on another human being, with any of the drugs described herein, without being familiar with that drug’s action and aware of the physical and/or mental disturbance or harm it might cause, is acting irresponsibly and immorally, whether or not he is doing so within the bounds of the law.”
The copyright for Book I of TiHKAL has been reserved in all forms and it may not be distributed. Book II of TiHKAL may be distributed for non-commercial reproduction provided that the introductory information, copyright notice, cautionary notice and ordering information remain attached.
TiHKAL is the extraordinary record of the authors’ years exploring the chemistry and transformational power of tryptamines. This book belongs in the library of anyone seeking a rational, enlightened and candid perspective on psychedelic drugs.
Though Sasha and Ann have put Book II of TiHKAL in the public domain, available to anyone, I strongly encourage you to buy a copy. We owe them — and there’s still nothing quite like holding a real book in your hands.
TiHKAL (ISBN 0-9630096-9-9) is available for US$24.50 (plus $10 domestic first-class shipping) from Transform Press.Transform Press,
Berkeley, CA 94701
510 · 934 · 4930 (voice)
510 · 934 · 5999 (fax)